03.07.2015 Views

WASATCH FUNDS - Curian Clearing

WASATCH FUNDS - Curian Clearing

WASATCH FUNDS - Curian Clearing

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>WASATCH</strong> CORE GROWTH FUND (WGROX / WIGRX) — Management Discussion<br />

MARCH 31, 2015 (UNAUDITED)<br />

The Wasatch Core Growth Fund is managed by a team of<br />

Wasatch portfolio managers led by JB Taylor and Paul Lambert.<br />

JB Taylor<br />

Lead Portfolio Manager<br />

Paul Lambert<br />

Portfolio Manager<br />

OVERVIEW<br />

Small-cap stocks<br />

were strong in the<br />

first quarter of<br />

2015. After a year<br />

of trailing the S&P<br />

500 ® Index, small<br />

caps outperformed<br />

their larger-cap<br />

counterparts for<br />

the second quarter<br />

in a row. It was<br />

also another quarter in which the average small-cap manager<br />

underperformed. In this context, we were pleased that the<br />

Wasatch Core Growth Fund — Investor Class gained 7.30%<br />

and outperformed its benchmarks. The Russell 2000 Index<br />

advanced 4.32% and the Russell 2000 Growth Index<br />

returned 6.63%. We attribute our performance to solid<br />

stock-picking, which was strong across the Fund.<br />

DETAILS OF THE QUARTER<br />

It’s impossible to discuss the current market environment<br />

without addressing the phenomenal performance of the<br />

biotechnology industry. The average biotechnology stock in<br />

the Russell 2000 Growth Index was up approximately 15%<br />

in the quarter, more than double the overall Index return.<br />

This has been an impressive run — in 13 of the last 16 quarters<br />

biotechnology stocks have outperformed.<br />

The Fund’s minimal exposure to biotech companies has<br />

been a huge headwind. Most biotech companies go years<br />

without generating profits, and a company with great science<br />

may still fail to win Food and Drug Administration<br />

approval for its products. More biotech companies will fail<br />

than succeed, and the big winners heavily skew the<br />

industry’s performance.<br />

We want to own profitable companies like Icon plc,<br />

which provides clinical-research services to the biotechnology<br />

industry. We call this a “picks and shovels”<br />

approach — selling goods and services to a well-capitalized<br />

group of risk-takers. In the first quarter, Icon was among<br />

our best contributors.<br />

We will continue to execute our current strategy for the<br />

biotech industry, running a large underweight versus the<br />

benchmark, but occasionally rifle-shooting for a company<br />

with great science, a proven management team and a market<br />

valuation that is small relative to the company’s endmarket<br />

potential.<br />

The U.S. dollar continued to strengthen in the first quarter<br />

and the price of oil is still nearly 50% below the price last<br />

summer. Low-priced oil helps a company like our small-cap<br />

airline Allegiant Travel Co., where fuel is the largest single<br />

cost item in the income statement. Allegiant was the top<br />

contributor to the Fund’s performance in the first quarter.<br />

Although the overall backdrop for small-cap fundamentals<br />

is the best we have seen in a long time, valuations<br />

remain high for U.S. small caps. The number of companies<br />

trading with market valuations greater than 10 times revenues,<br />

a valuation metric we would consider “extreme,”<br />

remains close to an all-time high. A historically low number<br />

of companies today qualify as inexpensive (less than 1 times<br />

revenues). We believe we must stay disciplined with our<br />

valuations in such an elevated market. At quarter-end, the<br />

Fund’s price-to-earnings (P/E) multiple was roughly in line<br />

with both indices, but we have been capturing much betterthan-average<br />

revenue and earnings growth rates.<br />

It’s not customary for us to outperform in such a strong<br />

small-cap market. Our focus on high-quality companies<br />

typically has resulted in the Fund giving up some performance<br />

relative to the indices in the strongest markets, but it<br />

has often outperformed by a wide margin in choppier markets.<br />

To illustrate, on the 100 worst market days between<br />

December 31, 2012 and March 31, 2015, the Russell 2000<br />

Growth Index was down, on average, -1.6%, and the<br />

Wasatch Core Growth Fund outperformed on 92% of those<br />

days. We attribute the Fund’s recent outperformance to the<br />

underlying fundamentals of our portfolio companies. For<br />

example, the Fund’s second-best contributor was Credit<br />

Acceptance Corp., a non-prime auto-finance company that<br />

we believe has an exceptional management team and a track<br />

record for prudently allocating capital.<br />

Life Time Fitness, Inc. and Polypore International, Inc.<br />

announced that they were being acquired. Even though<br />

these two companies were top contributors for the quarter,<br />

we didn’t spend much time cheering. When they have been<br />

acquired, we’ll need to find businesses of comparable<br />

strength to replace them with.<br />

From our first purchase in 2005 through the end of 2012,<br />

MSC Industrial Direct Co., Inc. executed superbly and<br />

continued to take profitable share in a large maintenance,<br />

repair and operations market. Since then, the company has<br />

had a difficult time turning investment spending on new<br />

initiatives into profitable growth.<br />

Cornerstone OnDemand, Inc. posted a solid fourth quarter,<br />

but management gave disappointing guidance. With<br />

30% of Cornerstone’s revenues generated outside the U.S.,<br />

the strong dollar will make the company’s growth rate look<br />

lower in the short term. We like Cornerstone and believe it<br />

is one of the most attractively valued software-as-a-service<br />

(SaaS) businesses in the market.<br />

OUTLOOK<br />

From where we sit, the operating environment for U.S.<br />

small-cap companies continues to improve and the average<br />

U.S. small-cap company’s fundamentals are accelerating.<br />

This has provided a good environment for us to execute<br />

our bottom-up selection process, as we focus on what we<br />

consider to be the highest-quality and best-managed longduration<br />

growth companies. Our companies have<br />

consistently posted revenue and earnings growth rates that<br />

are higher than the average company. The ability to<br />

capture above-average earnings growth, compounded<br />

patiently over time, is at the center of our time-tested<br />

investment philosophy.<br />

Thank you for the opportunity to manage your assets.<br />

Current and future holdings are subject to risk.<br />

4

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!